Skip to main content

A group comparative, placebo-controlled, double-blind trial of the efficacy and safety of galantamine hydrobromide, 7.5 mg (6 mg galantamine base) TID, 10 mg (8 mg galantamine base) TID and 15 mg (12 mg galantamine base) TID taken orally for 12 weeks in

A group comparative, placebo-controlled, double-blind trial of the efficacy and safety of galantamine hydrobromide, 7.5 mg (6 mg galantamine base) TID, 10 mg (8 mg galantamine base) TID and 15 mg (12 mg galantamine base) TID taken orally for 12 weeks in patients with a diagnosis of senile dementia of the Alzheimer’s type


CSR Summary

Not Available


NCT Number

Not Available


Data Specification

Not Yet Available


Annotated CRF

Not Yet Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Galantamine hydrobromide
Product Name
RAZADYNE®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
285
Product Class
Alzheimer's Disease - Cholinesterase Inhibitors
Sponsor Protocol Number
GAL-93-01
Data Holder
Johnson & Johnson
Condition Studied
Alzheimer Disease

Supporting Documentation

Clinical Study Report
Collected Datasets
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.